STOCK TITAN

[Form 4] VOLITIONRX LTD Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Salvatore Thomas Butera, listed as an officer (CEO - Volition Veterinary) and director of VolitionRx Ltd (VNRX), reported transactions dated 09/28/2025 on a Form 4. The filing shows 5,230 shares of common stock disposed of at $0.605 per share by means of share retention by the issuer to satisfy tax withholding on the settlement of 19,125 restricted stock units; the filing states no shares were sold by the reporting person or the company. The reporting person beneficially owns 332,285 shares following the transaction, and 99,350 shares are jointly owned with his spouse.

Salvatore Thomas Butera, elencato come dirigente (CEO - Volition Veterinary) e direttore di VolitionRx Ltd (VNRX), ha riportato operazioni in data 28/09/2025 in un Form 4. La registrazione mostra la cessione di 5.230 azioni ordinarie a 0,605$ per azione mediante ritenzione delle azioni da parte dell’emittente per soddisfare le ritenute fiscali sul regolamento di 19.125 unità di azioni vincolate; la registrazione indica che né la persona che segnala né l’azienda hanno venduto azioni. La persona che segnala detiene beneficiamente 332.285 azioni dopo la transazione, e 99.350 azioni sono detenute congiuntamente con il coniuge.
Salvatore Thomas Butera, listado como directivo (CEO - Volition Veterinary) y director de VolitionRx Ltd (VNRX), reportó transacciones fechadas el 28/09/2025 en un Formulario 4. La presentación muestra la disposición de 5,230 acciones comunes a 0,605$ por acción mediante retención de acciones por parte del emisor para satisfacer la retención fiscal al liquidar 19,125 unidades de acciones restringidas; el formulario indica que ni la persona reportante ni la empresa vendieron acciones. La persona reportante posee beneficiosamente 332,285 acciones tras la transacción, y 99,350 acciones son de propiedad conjunta con su cónyuge.
Salvatore Thomas Butera는 Volition Veterinary의 CEO 겸 임원으로, VolitionRx Ltd (VNRX)의 이사로 등재되어 있으며, 2025-09-28에 Form 4에 거래를 보고했다. 공시는 주당 0.605달러의 일반주 5,230주를 발행사가 세금 보유를 충당하기 위한 주식 보유로 처리하여 매각한 것으로 나타내며, 19,125주로 제약된 주식단위의 정산에 대한 보유를 충당한다는 내용이다; 보고서에는 보고자나 회사가 주식을 매도한 것으로 기재되어 있지 않다. 거래 후 보고자는 실질적으로 332,285주를 보유하며, 99,350주는 배우자와 공동으로 소유한다.
Salvatore Thomas Butera, répertorié comme dirigeant (CEO - Volition Veterinary) et administrateur de VolitionRx Ltd (VNRX), a déclaré des transactions datées du 28/09/2025 dans un Formulaire 4. Le dépôt indique la cession de 5 230 actions ordinaires à 0,605 $ par action par rétention d’actions par l’émetteur pour satisfaire les retenues fiscales lors du règlement de 19 125 unités d’actions restreintes; le formulaire précise qu’aucune action n’a été vendue par la personne déclarant ou par la société. Le déclarant détient avantageusement 332 285 actions à la suite de la transaction, et 99 350 actions sont détenues conjointement avec son conjoint.
Salvatore Thomas Butera, als Geschäftsführer (CEO - Volition Veterinary) und Direktor von VolitionRx Ltd (VNRX) geführt, meldete Transaktionen vom 28.09.2025 in einem Formular 4. Die Einreichung zeigt den Verzicht auf 5.230 Stammaktien zu 0,605 $ pro Aktie durch Verknappung der Aktien durch den Emittenten, um Steuern bei der Abwicklung von 19.125 eingeschränkten Aktien-Einheiten zu decken; im Formular wird angegeben, dass weder die meldende Person noch das Unternehmen Aktien verkauft haben. Die meldende Person besitzt nach der Transaktion vorteilhaft 332.285 Aktien, und 99.350 Aktien sind gemeinschaftlich mit dem Ehepartner Eigentum.
سالفاتوري توماس بوتيرا، المدرج كمسؤول تنفيذي (CEO - Volition Veterinary) وعضو مجلس إدارة VolitionRx Ltd (VNRX)، أقرّ بوجود معاملات بتاريخ 2025/09/28 في نموذج 4. تُظهر الإيداع بيع 5,230 سهماً من الأسهم العادية بسعر 0.605 دولار للسهم عن طريق الاحتجاز من قبل المصدر لتلبية أقساط الضرائب عند تسوية 19,125 وحدة أسهم مقيدة؛ ويذكر الإيداع أنه لم يتم بيع أي أسهم من قبل الشخص المبلغ أو الشركة. يملك الشخص المبلغ ملكية مفيدة قدرها 332,285 سهماً بعد الصفقة، و99,350 سهماً مملوكة بشكل مشترك مع زوجته.
Salvatore Thomas Butera,作为Volition Veterinary的CEO兼高级管理人员及VolitionRx Ltd (VNRX)的董事,被列入,于 2025-09-28 在 Form 4 上报告交易。申报显示以每股0.605美元的价格处置5,230股普通股,方式为由发行人留存股份以满足因清算19,125单位受限股票单位而产生的税收预扣;申报称报告人或公司未出售任何股份。交易后,报告人实际拥有332,285股,且99,350股与其配偶共同拥有。
Positive
  • Tax withholding handled via share retention by the issuer rather than an open-market sale, avoiding immediate selling pressure
  • Reporting person retains significant beneficial ownership (332,285 shares) after the RSU settlement, indicating continued alignment with shareholders
Negative
  • Reduction in outstanding shares for the reporting person due to tax-withholding cancellation of 5,230 shares
  • Joint ownership of 99,350 shares with spouse reduces the number of solely individually controlled shares

Insights

TL;DR Officer satisfied RSU tax withholding through company retention; no open-market sale reported, so immediate market impact is minimal.

The Form 4 documents a non-market disposal of 5,230 shares retained by the issuer to cover tax withholding on 19,125 RSUs. Because the shares were cancelled by the company for tax purposes rather than sold in the market, there is no direct selling pressure from the reporting person. The reporting person still beneficially owns 332,285 shares, indicating continued equity exposure. This disclosure is routine for RSU settlements and is informational rather than a material change in control or ownership.

TL;DR Disclosure aligns with standard insider reporting for RSU tax withholding; no governance concerns evident from the transaction details.

The filing clarifies the mechanism used to satisfy tax obligations upon RSU settlement, specifying that shares were retained by VolitionRx rather than sold by the insider. The report identifies the reporting person as an officer and director and notes joint ownership for 99,350 shares with his spouse. There are no disclosed resignations, option grants, or unusual derivative transactions in this Form 4 that would raise corporate governance flags.

Salvatore Thomas Butera, elencato come dirigente (CEO - Volition Veterinary) e direttore di VolitionRx Ltd (VNRX), ha riportato operazioni in data 28/09/2025 in un Form 4. La registrazione mostra la cessione di 5.230 azioni ordinarie a 0,605$ per azione mediante ritenzione delle azioni da parte dell’emittente per soddisfare le ritenute fiscali sul regolamento di 19.125 unità di azioni vincolate; la registrazione indica che né la persona che segnala né l’azienda hanno venduto azioni. La persona che segnala detiene beneficiamente 332.285 azioni dopo la transazione, e 99.350 azioni sono detenute congiuntamente con il coniuge.
Salvatore Thomas Butera, listado como directivo (CEO - Volition Veterinary) y director de VolitionRx Ltd (VNRX), reportó transacciones fechadas el 28/09/2025 en un Formulario 4. La presentación muestra la disposición de 5,230 acciones comunes a 0,605$ por acción mediante retención de acciones por parte del emisor para satisfacer la retención fiscal al liquidar 19,125 unidades de acciones restringidas; el formulario indica que ni la persona reportante ni la empresa vendieron acciones. La persona reportante posee beneficiosamente 332,285 acciones tras la transacción, y 99,350 acciones son de propiedad conjunta con su cónyuge.
Salvatore Thomas Butera는 Volition Veterinary의 CEO 겸 임원으로, VolitionRx Ltd (VNRX)의 이사로 등재되어 있으며, 2025-09-28에 Form 4에 거래를 보고했다. 공시는 주당 0.605달러의 일반주 5,230주를 발행사가 세금 보유를 충당하기 위한 주식 보유로 처리하여 매각한 것으로 나타내며, 19,125주로 제약된 주식단위의 정산에 대한 보유를 충당한다는 내용이다; 보고서에는 보고자나 회사가 주식을 매도한 것으로 기재되어 있지 않다. 거래 후 보고자는 실질적으로 332,285주를 보유하며, 99,350주는 배우자와 공동으로 소유한다.
Salvatore Thomas Butera, répertorié comme dirigeant (CEO - Volition Veterinary) et administrateur de VolitionRx Ltd (VNRX), a déclaré des transactions datées du 28/09/2025 dans un Formulaire 4. Le dépôt indique la cession de 5 230 actions ordinaires à 0,605 $ par action par rétention d’actions par l’émetteur pour satisfaire les retenues fiscales lors du règlement de 19 125 unités d’actions restreintes; le formulaire précise qu’aucune action n’a été vendue par la personne déclarant ou par la société. Le déclarant détient avantageusement 332 285 actions à la suite de la transaction, et 99 350 actions sont détenues conjointement avec son conjoint.
Salvatore Thomas Butera, als Geschäftsführer (CEO - Volition Veterinary) und Direktor von VolitionRx Ltd (VNRX) geführt, meldete Transaktionen vom 28.09.2025 in einem Formular 4. Die Einreichung zeigt den Verzicht auf 5.230 Stammaktien zu 0,605 $ pro Aktie durch Verknappung der Aktien durch den Emittenten, um Steuern bei der Abwicklung von 19.125 eingeschränkten Aktien-Einheiten zu decken; im Formular wird angegeben, dass weder die meldende Person noch das Unternehmen Aktien verkauft haben. Die meldende Person besitzt nach der Transaktion vorteilhaft 332.285 Aktien, und 99.350 Aktien sind gemeinschaftlich mit dem Ehepartner Eigentum.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Butera Salvatore Thomas

(Last) (First) (Middle)
1489 WEST WARM SPRINGS ROAD
SUITE 110

(Street)
HENDERSON NV 89014

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
VOLITIONRX LTD [ VNRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CEO - Volition Veterinary
3. Date of Earliest Transaction (Month/Day/Year)
09/28/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/28/2025 F 5,230(1) D $0.605 332,285 D
Common Stock 99,350 D(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 19,125 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction.
2. These shares of common stock are jointly owned by the reporting person and his spouse.
Remarks:
/s/ Salvatore Thomas Butera 09/30/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Salvatore Thomas Butera report on Form 4 for VNRX?

The Form 4 reports a 09/28/2025 transaction where 5,230 shares were retained by VolitionRx to satisfy tax withholding on the settlement of 19,125 RSUs; no open-market sale was reported.

How many shares does the reporting person beneficially own after the transaction?

The filing states the reporting person beneficially owns 332,285 shares following the reported transaction.

Were any shares sold in the market according to this Form 4?

No. The filing explicitly states no shares were sold by the reporting person or VolitionRx; shares were retained for tax withholding.

What is the reported price associated with the retained shares?

The retained 5,230 shares are shown with a price of $0.605 per share in the Form 4.

What does footnote 2 in the Form 4 indicate?

Footnote 2 indicates that 99,350 shares of common stock are jointly owned by the reporting person and his spouse.
Volitionrx

NYSE:VNRX

VNRX Rankings

VNRX Latest News

VNRX Latest SEC Filings

VNRX Stock Data

66.94M
86.70M
17.84%
22.29%
0.28%
Medical Devices
In Vitro & in Vivo Diagnostic Substances
Link
United States
HENDERSON